Published in J Hypertens on January 01, 2012
Microalbuminuria breakthrough under chronic renin-angiotensin-aldosterone system suppression. J Hypertens (2012) 1.45
Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA (2002) 12.29
Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial. J Am Coll Cardiol (2011) 3.08
Blood pressure components and end-stage renal disease in persons with chronic kidney disease: the Kidney Early Evaluation Program (KEEP). Arch Intern Med (2012) 2.74
Management of high blood pressure in Blacks: an update of the International Society on Hypertension in Blacks consensus statement. Hypertension (2010) 2.47
Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Circulation (2008) 2.41
Blood pressure control and improved cardiovascular outcomes in the International Verapamil SR-Trandolapril Study. Hypertension (2007) 2.37
The rationale and design of the AASK cohort study. J Am Soc Nephrol (2003) 2.34
Design and statistical aspects of the African American Study of Kidney Disease and Hypertension (AASK). J Am Soc Nephrol (2003) 2.21
Comparison of measured GFR, serum creatinine, cystatin C, and beta-trace protein to predict ESRD in African Americans with hypertensive CKD. Am J Kidney Dis (2011) 2.11
ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation (2011) 1.97
Is it time for a cardiovascular primary prevention trial in the elderly? Stroke (2006) 1.69
Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 Trial. Clin Cardiol (2012) 1.66
Control of blood pressure and other cardiovascular risk factors at different practice settings: outcomes of care provided to diabetic women compared to men. J Clin Hypertens (Greenwich) (2005) 1.51
Effects of drospirenone/17-beta estradiol on blood pressure and potassium balance in hypertensive postmenopausal women. Am J Hypertens (2005) 1.49
Sodium-glucose cotransporter-2 inhibitors and blood pressure decrease: a valuable effect of a novel antidiabetic class? J Hypertens (2015) 1.42
Intervention Associated Acute Kidney Injury and Long-Term Cardiovascular Outcomes. Am J Nephrol (2015) 1.39
Hypertension and CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES), 1999-2004. Am J Kidney Dis (2008) 1.38
Association between hyperuricemia and incident heart failure among older adults: a propensity-matched study. Int J Cardiol (2009) 1.38
Beneficial effects of oral magnesium supplementation on insulin sensitivity and serum lipid profile. Med Sci Monit (2010) 1.27
Risk of hyperkalemia in nondiabetic patients with chronic kidney disease receiving antihypertensive therapy. Arch Intern Med (2009) 1.19
Race and sex differences in hypertension control in CKD: results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis (2008) 1.18
Prevalence and associations of anemia of CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004. Am J Kidney Dis (2008) 1.16
Pheochromocytoma in pregnancy: a case series and review. Hypertension (2010) 1.14
The controversial effects of thiazolidinediones on cardiovascular morbidity and mortality. Int J Cardiol (2008) 1.14
Effects of low-dose atorvastatin on arterial stiffness and central aortic pressure augmentation in patients with hypertension and hypercholesterolemia. Am J Hypertens (2013) 1.12
Increase in oxidative stress but not in antioxidant capacity with advancing stages of chronic kidney disease. Am J Nephrol (2007) 1.11
Microalbuminuria and chronic kidney disease as risk factors for cardiovascular disease. Nephrol Dial Transplant (2006) 1.07
International expert consensus statement: Percutaneous transluminal renal denervation for the treatment of resistant hypertension. J Am Coll Cardiol (2013) 1.05
A propensity-matched study of hypertension and increased stroke-related hospitalization in chronic heart failure. Am J Cardiol (2008) 1.02
Carvedilol in hypertension treatment. Vasc Health Risk Manag (2008) 1.02
Oral potassium supplement use and outcomes in chronic heart failure: a propensity-matched study. Int J Cardiol (2009) 1.02
Mild hyperkalemia and outcomes in chronic heart failure: a propensity matched study. Int J Cardiol (2009) 1.01
Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy. Am J Nephrol (2014) 1.01
A propensity-matched study of low serum potassium and mortality in older adults with chronic heart failure. Int J Cardiol (2008) 0.99
Pathogenesis and clinical physiology of hypertension. Cardiol Clin (2010) 0.97
Dysglycemia predicts cardiovascular and kidney disease in the Kidney Early Evaluation Program. J Clin Hypertens (Greenwich) (2010) 0.94
Effects of thiazolidinediones beyond glycaemic control. Curr Pharm Des (2009) 0.93
Gender disparity in outcomes of care and management for diabetes and the metabolic syndrome. Curr Diab Rep (2006) 0.93
Oral magnesium supplementation reduces ambulatory blood pressure in patients with mild hypertension. Am J Hypertens (2009) 0.92
Malnutrition-inflammation modifies the relationship of cholesterol with cardiovascular disease. J Am Soc Nephrol (2010) 0.92
Using an established telehealth model to train urban primary care providers on hypertension management. J Clin Hypertens (Greenwich) (2011) 0.92
Pathogenesis and treatment of microalbuminuria in patients with diabetes: the road ahead. J Clin Hypertens (Greenwich) (2009) 0.92
Differences between office and 24-hour blood pressure control in hypertensive patients with CKD: A 5,693-patient cross-sectional analysis from Spain. Am J Kidney Dis (2013) 0.91
Hemodialysis reduces augmentation index but not aortic or brachial pulse wave velocity in dialysis-requiring patients. Am J Nephrol (2011) 0.89
Should ambulatory blood pressure monitoring be mandatory for future studies in resistant hypertension: a perspective. J Hypertens (2012) 0.88
Prevention of microalbuminuria in patients with type 2 diabetes: what do we know? J Clin Hypertens (Greenwich) (2010) 0.88
Single-pill combination of telmisartan/amlodipine versus amlodipine monotherapy in diabetic hypertensive patients: an 8-week randomized, parallel-group, double-blind trial. Clin Ther (2012) 0.86
Association of race and body mass index with ESRD and mortality in CKD stages 3-4: results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis (2012) 0.86
Arterial stiffness: a novel cardiovascular risk factor in kidney disease patients. Curr Vasc Pharmacol (2015) 0.85
Ambulatory blood pressure monitoring: an invaluable tool comes of age for patients with chronic kidney disease? Am J Nephrol (2012) 0.85
Impact of Renal Denervation on Patients With Obstructive Sleep Apnea and Resistant Hypertension - Insights From the SYMPLICITY HTN-3 Trial. Circ J (2016) 0.85
Should nephrologists use beta-blockers? A perspective. Nephrol Dial Transplant (2008) 0.82
Blood pressure and serum potassium levels in hypertensive patients receiving or not receiving antihypertensive treatment. Clin Exp Hypertens (2007) 0.82
Status of Diabetes Care: New Challenges, New Concepts, New Measures--Focusing on the Future! Diabetes Care (2015) 0.82
Determinants and changes associated with aldosterone breakthrough after angiotensin II receptor blockade in patients with type 2 diabetes with overt nephropathy. Clin J Am Soc Nephrol (2013) 0.81
Status of Diabetes Care: "It just doesn't get any better . . . or does it?". Diabetes Care (2014) 0.81
Treatment and control of high blood pressure in adults. Cardiol Clin (2010) 0.81
Total protein, albumin and low-molecular-weight protein excretion in HIV-positive patients. BMC Nephrol (2012) 0.81
Slow intravenous iron administration does not aggravate oxidative stress and inflammatory biomarkers during hemodialysis: a comparative study between iron sucrose and iron dextran. Am J Nephrol (2007) 0.80
The impact of diabetic autonomic neuropathy on the incretin effect. Med Sci Monit (2008) 0.80
Diabetic nephropathy: Endothelin antagonism for diabetic nephropathy. Nat Rev Nephrol (2010) 0.80
Compliance with a structured weight loss program is associated with reduced systolic blood pressure in obese patients with chronic kidney disease. Am J Hypertens (2012) 0.80
Microalbuminuria. Clin Lab Med (2006) 0.80
Diverse effects of interdialytic intervals on central wave augmentation in haemodialysis patients. Nephrol Dial Transplant (2013) 0.79
Effects of nebivolol on aortic compliance in patients with diabetes and maximal renin angiotensin system blockade: the EFFORT study. J Clin Hypertens (Greenwich) (2013) 0.79
Dynamic resistant hypertension patterns as predictors of cardiovascular morbidity: a 4-year prospective study. J Hypertens (2014) 0.79
Elevated asymmetric dimethylarginine is associated with oxidant stress aggravation in patients with early stage autosomal dominant polycystic kidney disease. Kidney Blood Press Res (2014) 0.79
Efficacy of baroreflex activation therapy for the treatment of resistant hypertension. EuroIntervention (2013) 0.78
Prevalence of Hyperkalemia in Diabetic and Non-Diabetic Patients with Chronic Kidney Disease: A Nested Case-Control Study. Am J Nephrol (2015) 0.78
ImmunoDip: an improved screening method for microalbuminuria. Am J Nephrol (2004) 0.78
Hypertension following kidney injury. J Clin Hypertens (Greenwich) (2010) 0.78
Does evidence support renin-angiotensin system blockade for slowing nephropathy progression in elderly persons? Ann Intern Med (2009) 0.78
Building Momentum: Taking on the Real “Issues” of Diabetes Care! Diabetes Care (2016) 0.78
Evaluating the role of key learning theories in ECHO: a telehealth educational program for primary care providers. Prog Community Health Partnersh (2013) 0.78
Metabolic effects of beta-blockers: importance of dissociating newer from conventional agents. J Hypertens (2007) 0.78
Blood pressure, antihypertensive therapy and risk for renal injury in African-Americans. Curr Opin Nephrol Hypertens (2003) 0.78
Are renin-angiotensin-aldosterone system blockers distinguishable based on cardiovascular and renal outcomes in nephropathy? Postgrad Med (2009) 0.77
Use of a single target blood pressure level in type 2 diabetes mellitus for all cardiovascular risk reduction: comment on "intensive and standard blood pressure targets in patients with type 2 diabetes mellitus". Arch Intern Med (2012) 0.77
Effects of renin-angiotensin system inhibition on left atrial function of hypertensive patients: an echocardiographic tissue deformation imaging study. Am J Hypertens (2010) 0.77
Target Organ Damage in Hypertension. J Clin Hypertens (Greenwich) (2000) 0.77
The United Nations high level meeting addresses noncommunicable diseases, but where is hypertension? J Clin Hypertens (Greenwich) (2011) 0.77
Lessons learned from recent hypertension trials about kidney disease. Clin J Am Soc Nephrol (2005) 0.77
Influence of microalbuminuria in achieving blood pressure goals. Curr Opin Nephrol Hypertens (2008) 0.76
Ambulatory Blood Pressure Monitoring in the Diagnosis, Prognosis, and Management of Resistant Hypertension: Still a Matter of our Resistance? Curr Hypertens Rep (2015) 0.76
A cost-effectiveness analysis of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in diabetic nephropathy. J Clin Hypertens (Greenwich) (2007) 0.76
Telmisartan in incipient and overt diabetic renal disease. J Nephrol (2011) 0.76
Adverse effects of conventional thrice-weekly hemodialysis: is it time to avoid 3-day interdialytic intervals? Am J Nephrol (2015) 0.76
What lies behind the intense criticism of ALLHAT? J Hypertens (2004) 0.75
Renin-angiotensin system blockade and exercise-induced increase in aortic stiffness. J Clin Hypertens (Greenwich) (2014) 0.75
Metabolic syndrome and arterial stiffness: evidence for gender disparity and early effects of non-traditional risk factors? J Hypertens (2007) 0.75
Pediatrics: blood pressure target for renoprotection in children. Nat Rev Nephrol (2010) 0.75
Microscopic hematuria in adolescents and young adults and risk for end-stage renal disease. JAMA (2011) 0.75
Intensive lowering of systolic blood pressure to a target of less than 120 mm Hg has no effect on the rate of fatal and non-fatal major cardiovascular events in high-risk patients with type 2 diabetes. Evid Based Med (2010) 0.75
Initial single-pill combination therapy for cardiovascular risk factor management: it is not just convenience. J Hypertens (2013) 0.75
Initial combination antihypertensives: let's ACCELERATE. Lancet (2011) 0.75